STOCK TITAN

Scholar Rock to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, announced its participation in several upcoming investor conferences in June. The events include: UBS Obesity Therapeutics Day on May 23 at 9:00 a.m. ET, Jefferies Global Healthcare Conference on June 6 at 2:00 p.m. ET in New York City, and the 45th Annual Goldman Sachs Global Healthcare Conference on June 13 at 9:20 a.m. ET in Miami, Florida. These conferences will feature various presentations and virtual chats, with live webcasts available on Scholar Rock's website and archived for replay for approximately 90 days.

Positive
  • Scholar Rock is increasing visibility by participating in multiple high-profile investor conferences in June.
  • These events provide opportunities for Scholar Rock to present its innovative treatments for spinal muscular atrophy and cardiometabolic disorders to a broader audience.
  • The availability of live webcasts and archived replays for 90 days increases accessibility for investors and stakeholders.
Negative
  • No new clinical or financial data was mentioned in the PR, which could be perceived as a lack of significant immediate developments.
  • High frequency of similar announcements without substantial updates may lead to investor fatigue.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in June:

  • UBS Obesity Therapeutics Day: Scholar Rock is scheduled to participate in a virtual fireside chat at 9:00 a.m. ET on Thursday, May 23.
  • Jefferies Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:00 p.m. ET on Thursday, June 6 in New York City.
  • 45th Annual Goldman Sachs Global Healthcare Conference: Scholar Rock is scheduled to give a corporate presentation at 9:20 a.m. ET on Thursday, June 13 in Miami, Florida.

A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days.

About Scholar Rock

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.

Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Scholar Rock:

Investors


Rushmie Nofsinger

Scholar Rock

rnofsinger@scholarrock.com

ir@scholarrock.com

857-259-5573



Media

Molly MacLeod

Scholar Rock

mmacleod@scholarrock.com

media@scholarrock.com

802-579-599

Source: Scholar Rock

FAQ

When will Scholar Rock participate in the UBS Obesity Therapeutics Day?

Scholar Rock is scheduled to participate in a virtual fireside chat on May 23 at 9:00 a.m. ET.

When is Scholar Rock presenting at the Jefferies Global Healthcare Conference?

Scholar Rock will participate in a fireside chat on June 6 at 2:00 p.m. ET in New York City.

What is the date and time for Scholar Rock's presentation at the 45th Annual Goldman Sachs Global Healthcare Conference?

Scholar Rock is scheduled to present on June 13 at 9:20 a.m. ET in Miami, Florida.

Where can I access the live webcasts for Scholar Rock's investor conference presentations?

Live webcasts can be accessed on the Investors & Media section of Scholar Rock's website.

How long will the archived replays of Scholar Rock's conference presentations be available?

Archived replays will be available on Scholar Rock's website for approximately 90 days.

Scholar Rock Holding Corporation

NASDAQ:SRRK

SRRK Rankings

SRRK Latest News

SRRK Stock Data

2.42B
93.62M
1.07%
100.91%
16.53%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE